Read by QxMD icon Read

Clinical Medicine Insights. Oncology

Adrian Kinzel, Michael Ambrogi, Michael Varshaver, Eilon D Kirson
Background: Tumor treating fields (TTFields) are a non-invasive antimitotic therapy that delivers alternating electric fields via the Optune® system. The Phase III EF-14 trial in newly diagnosed glioblastoma multiforme (GBM) showed significantly improved progression-free, overall and long-term survival when Optune was used together with maintenance temozolomide (TMZ) compared with TMZ alone. Compliance (average monthly use) was associated with better clinical outcome. The first-generation Optune system weighed approximately 6 pounds (~2...
2019: Clinical Medicine Insights. Oncology
Ali Aljubran, Mahmoud A Elshenawy, Magdy Kandil, Muhammed N Zahir, Ahmed Shaheen, Ahmed Gad, Omar Alshaer, Ahmed Alzahrani, Abdelmonem Eldali, Shouki Bazarbashi
Background: Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local clinic practice. Patients and methods: Records of patients with confirmed colorectal cancer treated with regorafenib were reviewed. Clinical, pathological, and molecular data were collected. Efficacy and factors of possible prognostic significance were analyzed...
2019: Clinical Medicine Insights. Oncology
Marie Desjardin, Benjamin Bonhomme, Brigitte Le Bail, Serge Evrard, Véronique Brouste, Gregoire Desolneux, Marianne Fonck, Yves Bécouarn, Dominique Béchade
Background: Pre-operative chemotherapy for colorectal liver metastasis (CRLM) is thought to be the cause of hepatotoxicity of non-tumoural parenchyma. Studies on hepatotoxicity are contradictory. We investigated the impact of a single-line pre-operative chemotherapy on non-tumoural liver analysed by an expert hepatico-pancreatico-biliary pathologist, and the consequences on surgical outcomes. Patients and methods: Patients operated for CRLM, after a pure first-line pre-operative chemotherapy, were retrospectively included...
2019: Clinical Medicine Insights. Oncology
Erik Hägerström, Lotte Lindberg, Jens Bentzen, Kasper Brødbæk, Bo Zerahn, Bent Kristensen
Introduction: Cisplatin is used as treatment for several different malignancies and a well-known complication is irreversible kidney damage. To protect the kidneys, this treatment is often combined with mannitol infusion to promote osmotic diuresis. Earlier studies investigating the nephroprotective effect of mannitol have shown conflicting results. Objective: To investigate changes in kidney function in head and neck cancer patients treated with cisplatin with and without additional mannitol infusion...
2019: Clinical Medicine Insights. Oncology
Maiko Takeda, Takahiko Kasai, Maiko Naito, Akihiro Tamiya, Yoshihiko Taniguchi, Nobuhiko Saijo, Yoko Naoki, Kyoichi Okishio, Shigeki Shimizu, Kensuke Kojima, Akihiro Nagoya, Tetsuki Sakamoto, Tomoki Utsumi, Hyung-Eun Yoon, Akihide Matsumura, Shinji Atagi
Background: In recent years, the anti-programmed cell death 1 (PD-1) drug pembrolizumab (Keytruda) was approved for treatment of unresectable advanced non-small cell lung cancer (NSCLC) as first- or second-line therapy depending on the clone 22C3-programmed death-ligand 1 (PD-L1) immunohistochemical expression score by the companion diagnostic assay. We herein evaluated 22C3-PD-L1 expression of NSCLC in a single institution experience and compared it with clinicopathologic features. Materials and methods: We assessed 22C3-PD-L1 expressions of 411 patients with NSCLC from our institution, including in past specimens...
2019: Clinical Medicine Insights. Oncology
Giovanni Nicoletti, Marco Mario Tresoldi, Alberto Malovini, Sebastien Prigent, Manuela Agozzino, Angela Faga
Objectives: This study aims at the identification of the distribution of basal cell carcinomas (BCCs) in the auricle in correlation with the currently most credited sites of the embryonic fusion planes of the auricle. Methods: An overall number of 69 patients with 72 BCCs of the auricle were enrolled in the study over a period of 14 years, from June 2003 to October 2017. All the cases underwent medical preoperative digital photography and the specific location of each BCC was coded on an original full-size anatomical diagram of the auricle derived from the reports by Streeter, Wood-Jones, Park, Porter, and Minoux showing the currently most credited sites of the embryonic fusion planes arbitrarily featured as two 5-mm-wide ribbon-like areas: (1) the hyoid-mandibular fusion plane (HM-FP) running from the upper margin of the tragus toward the concha and then deflecting toward the lower margin of the tragus and (2) the free ear fold-hyoid fusion plane (FEFH-FP) running from the cranial-most portion of the helix to the mid-portion of the ascending helix...
2018: Clinical Medicine Insights. Oncology
Yanling Zhang, Heng Tang, Huaiyuan Hu, Xiang Yong
Primary leiomyomas of the thyroid are very rare. We here report a case of a 53-year-old woman with a painless mass at the right thyroid, revealed by physical examination. The patient underwent a lobectomy. Frozen sections showed a spindle cell tumor of the thyroid gland. The nuclei of some of the tumor cells were obviously enlarged and deeply stained. Pseudocapsule invasion was observed in small foci. Samples showed neither mitosis nor necrosis and the nature of the tumor was difficult to determine. Paraffin sections showed a well-circumscribed nodular composed of intersecting fascicles of spindled to slightly epithelioid cells with eosinophilic cytoplasm and blunt-ended, cigar-shaped nuclei...
2018: Clinical Medicine Insights. Oncology
(no author information available yet)
[This corrects the article DOI: 10.1177/1179554918782477.].
2018: Clinical Medicine Insights. Oncology
Ying-Wen Su, Chia-Yen Hung, Hung-Bun Lam, Yuan-Ching Chang, Po-Sheng Yang
The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and overall survival (OS) of patients with resected stage I-III TNBC who were treated with or without cisplatin-containing chemotherapy (CisCT or noCisCT) during 2004 and 2010. Of 129 patients, 25 received CisCT. In univariate analysis, the mean TTP for CisCT and noCisCT was 4...
2018: Clinical Medicine Insights. Oncology
Irfan Ahmad, Kundan Singh Chufal, Irfan Bashir, Chandi Prasad Bhatt, Ram Bajpai, Lalit Sharma, Sandeep Rathour
Purpose: To evaluate clinical outcomes and failure patterns in patients with locally advanced cervical cancer (LACC) treated definitively using image-guided volumetric-modulated arc therapy (IG-VMAT). Methods and materials: This retrospective review included 18 consecutively treated patients with LACC. Treatment consisted of IG-VMAT and concurrent chemotherapy followed by intracavitary radiotherapy. The primary end points were overall survival (OS) and disease-free survival (DFS)...
2018: Clinical Medicine Insights. Oncology
Homero Gonçalves, Maximiliano Ribeiro Guerra, Jane Rocha Duarte Cintra, Vívian Assis Fayer, Igor Vilela Brum, Maria Teresa Bustamante Teixeira
Objective: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors. Methods: This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated. Results: Triple-negative breast cancer corresponded to 19...
2018: Clinical Medicine Insights. Oncology
Adeyi A Adoga, John P Yaro, Joyce G Mugu, Chukwunonso J Mgbachi
Background: The risk factors for head and neck cancers (HNC) vary in different parts of the world. Objectives: To identify the risk factors for HNC and the correlation between these factors and the involved anatomical sites. Methods: We retrieved and analyzed health records of patients that met the inclusion criteria for HNC managed at our facility in a 10-year period using the International Classification of Diseases (ICD) version 10. Results: We studied 122 patients with a male to female ratio of 2...
2018: Clinical Medicine Insights. Oncology
B J Srinivasa, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia, D Tousif, Raghavendra Rao, Amritanshu Ram, Shekar Patil, Radheshyam Naik
Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients with MBC. Methods: In this study, a total of 45 eligible patients with MBC who received eribulin in HCG Cancer Speciality Center from November 2014 to March 2016 were prospectively analyzed...
2018: Clinical Medicine Insights. Oncology
Margherita Nannini, Giulia Dondi, Donatella Santini, Antonio De Leo, Angelo Paolo Dei Tos, Claudio Zamagni, Maristella Saponara, Lidia Gatto, Concetta Nigro, Paola Bertaccini, Maurizio Zompatori, Pierandrea De Iaco, Myriam Anna Perrone, Maria Abbondanza Pantaleo
Adenosarcomas are the rarest form of uterine sarcomas, and clinical experience with their management is still limited. Here, we reported 7 patients with uterine adenosarcoma referred to our institution, focusing on main pathologic features, their medical history, and long-term follow-up. Among these patients, we provided a detailed description of the medical history of a 49-year-old woman with advanced uterine adenosarcoma with sarcomatous overgrowth who presented a brilliant radiologic and pathologic response after 3 cycles of epirubicin and ifosfamide, ultimately achieving an extraordinary long-term outcome through an integrated surgical and medical approach...
2018: Clinical Medicine Insights. Oncology
Monira Haque, Nadia Hameed, Christopher T Perry, Elliot Carter, Wadad S Mneimneh
We report a case of malignant peritoneal mesothelioma (MPM) in a 31-year-old male with history of cerebral palsy, hydrocephalus, and ventriculoperitoneal shunt (VPS) placed since infancy. He presented with fever, abdominal pain and distension. Computed tomography scan revealed a thick-walled rim-enhancing fluid collection, interpreted as pseudocyst. Intraoperatively, diffuse nodular peritoneal thickening with adhesions was demonstrated. The resection specimen consisted of multiple membranous fragments displaying firm nodules...
2018: Clinical Medicine Insights. Oncology
William Paul Skelton, Jacqueline Castagno, Joel Cardenas-Goicoechea, Karen Daily, Anamaria Yeung, Merry Jennifer Markham
Objective: Bevacizumab is approved for use in combination with chemotherapy for metastatic/recurrent cervical cancer (CC), with increased survival/response rates. However, use of bevacizumab is not always feasible or safe. The purpose of this study was to identify the percentage of metastatic/recurrent CC patients at our institution who would have been eligible to receive bevacizumab. Methods: A retrospective study was conducted to identify metastatic/recurrent CC patients treated at UFHealth between 2006 and 2016...
2018: Clinical Medicine Insights. Oncology
Dipesh Uprety, Amir Bista, Yazhini Vallatharasu, Lubina Arjyal
No abstract text is available yet for this article.
2018: Clinical Medicine Insights. Oncology
Eoghan Malone, Lillian L Siu
Standard treatment in head and neck squamous cell carcinoma (HNSCC) is limited currently with decisions being made primarily based on tumor location, histology, and stage. The role of the human papillomavirus in risk stratification is actively under clinical trial evaluations. The molecular complexity and intratumoral heterogeneity of the disease are not actively integrated into management decisions of HNSCC, despite a growing body of knowledge in these areas. The advent of the genomic era has delivered vast amounts of information regarding different cancer subtypes and is providing new therapeutic targets, which can potentially be elucidated using next-generation sequencing and other modern technologies...
2018: Clinical Medicine Insights. Oncology
Maher Jedi, Graeme P Young, Susanne K Pedersen, Erin L Symonds
The genes BCAT1 and IKZF1 are hypermethylated in colorectal cancer (CRC), but little is known about how this relates to gene expression. This study assessed the relationship between methylation and gene expression of BCAT1 and IKZF1 in CRC and adjacent non-neoplastic tissues. The tissues were obtained at surgery from 36 patients diagnosed with different stages of CRC (stage I n = 8, stage II n = 13, stage III n = 10, stage IV n = 5). Methylated BCAT1 and IKZF1 were detected in 92% and 72% CRC tissues, respectively, with levels independent of stage ( P  > ...
2018: Clinical Medicine Insights. Oncology
Isabel Tena, Garima Gupta, Marcos Tajahuerce, Marta Benavent, Manuel Cifrián, Alejandro Falcon, María Fonfria, Maribel Del Olmo, Rosa Reboll, Antonio Conde, Francisca Moreno, Julia Balaguer, Adela Cañete, Rosana Palasí, Pilar Bello, Alfredo Marco, José Luis Ponce, Juan Francisco Merino, Antonio Llombart, Alfredo Sanchez, Karel Pacak
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B ( SDHB ) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of metronomic schemes (MS) of chemotherapy in mPHEO/PGL treatment. We report 2 patients with SDHB -related mPGL who received a regimen consisting of MS temozolomide (TMZ) and high-dose lanreotide after progression on both CVD chemotherapy and high-dose lanreotide...
2018: Clinical Medicine Insights. Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"